{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T21:31:43Z","timestamp":1784064703709,"version":"3.55.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infectious Diseases Now"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.idnow.2025.105185","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T01:36:45Z","timestamp":1762393005000},"page":"105185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5677-3027","authenticated-orcid":false,"given":"Andreas","family":"Chiabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankara","family":"Nykam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Fomenky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2180-7829","authenticated-orcid":false,"given":"Lucas M.","family":"Tanlaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franklin N.","family":"Ngueiwoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christabelle","family":"Ewane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa M.","family":"Fozao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Nsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.idnow.2025.105185_b0005","unstructured":"UNAIDS [Internet]. 2020. UNAIDS data 2020 [cited November 17, 2023]. Available from: https:\/\/www.unaids.org\/en\/resources\/documents\/2020\/unaids-data."},{"issue":"6","key":"10.1016\/j.idnow.2025.105185_b0010","first-page":"78","article-title":"2022 HIV Market Report: the state of the HIV market in low- and middle-income countries","volume":"17","author":"Mogojwe","year":"2022","journal-title":"Clinton Health Access Initiative"},{"issue":"3","key":"10.1016\/j.idnow.2025.105185_b0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.idnow.2025.105185_b0020","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/infdis\/jix409","article-title":"Key factors influencing the emergence of human immunodeficiency virus drug resistance in low- and middle-income countries","volume":"216","author":"Wallis","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.idnow.2025.105185_b0025","unstructured":"World Health Organization [Internet]. 2017. HIV drug resistance report 2017 [cited November 25, 2023]. Available from: https:\/\/iris.who.int\/handle\/10665\/255896."},{"issue":"3","key":"10.1016\/j.idnow.2025.105185_b0030","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/S2352-3018(17)30190-X","article-title":"Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study","volume":"5","author":"Phillips","year":"2018","journal-title":"Lancet HIV"},{"issue":"1","key":"10.1016\/j.idnow.2025.105185_b0035","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12962-019-0195-2","article-title":"Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients","volume":"17","author":"Punekar","year":"2019","journal-title":"Cost Eff Resour Alloc"},{"issue":"3","key":"10.1016\/j.idnow.2025.105185_b0040","first-page":"837","article-title":"Efficacy and tolerance of dolutegravir-based combined ART in perinatally HIV-1-infected adolescents: a French multicentre retrospective study","volume":"72","author":"Briand","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.idnow.2025.105185_b0045","doi-asserted-by":"crossref","DOI":"10.1177\/23259582221109613","article-title":"Adherence, effectiveness and safety of Dolutegravir based antiretroviral regimens among HIV infected children and adolescents in Tanzania","volume":"21","author":"Mutagonda","year":"2022","journal-title":"J Int Assoc Provid AIDS Care"},{"issue":"4","key":"10.1016\/j.idnow.2025.105185_b0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/QAD.0000000000003154","article-title":"Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya","volume":"36","author":"Kingwara","year":"2022","journal-title":"AIDS"},{"key":"10.1016\/j.idnow.2025.105185_b0055","unstructured":"UNAIDS [Internet]. 2023. Cameroon National Strategic Plan For fight against HIVAIDS and STIs 2021-2023 [cited November 17, 2023]. Available from: https:\/\/hivpreventioncoalition.unaids.org\/sites\/default\/files\/attachments\/cameroon-national-strategic-plan-for-fight-against-hivaids-and-stis-2021-2023.pdf."},{"issue":"1","key":"10.1016\/j.idnow.2025.105185_b0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/v15010018","article-title":"Dolutegravir-based Regimen Ensures High virological success despite prior exposure to Efavirenz-based First-LINE ART in Cameroon: an evidence of a successful transition Model","volume":"15","author":"Semengue","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.idnow.2025.105185_b0065","doi-asserted-by":"crossref","unstructured":"Maghembe AA, Boer MS de, Marikias G, Amour C, Mahande MJ,. HIV Viral suppression and associated factors among children and adolescents on a Dolutegravir (dtg) based antiretroviral regimen in Tanzania Mainland. medRxiv. 2023.05.17.23290106.","DOI":"10.1101\/2023.05.17.23290106"},{"issue":"10","key":"10.1016\/j.idnow.2025.105185_b0070","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.1093\/jac\/dkac259","article-title":"Integrase inhibitors in children and adolescents: clinical use and resistance","volume":"77","author":"Torres-Fernandez","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.idnow.2025.105185_b0075","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238052","article-title":"Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV","volume":"15","author":"Correa","year":"2020","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.idnow.2025.105185_b0080","article-title":"Treatment outcomes of Dolutegravir- versus Efavirenz-based highly active antiretroviral therapy regimens among treatment-naive people living with HIV","volume":"15","author":"Mahale","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.idnow.2025.105185_b0085","doi-asserted-by":"crossref","unstructured":"NAMSAL ANRS 12313 Study Group; Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S, et al. Dolutegravir-Based or Low-Dose Efavirenz\u2013Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326.","DOI":"10.1056\/NEJMoa1904340"},{"key":"10.1016\/j.idnow.2025.105185_b0090","article-title":"A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-na\u00efve patients with advanced HIV infection in Nanjing","volume":"13","author":"Zhong","year":"2023","journal-title":"China Front Immunol"},{"key":"10.1016\/j.idnow.2025.105185_b0095","doi-asserted-by":"crossref","DOI":"10.31744\/einstein_journal\/2023AO0156","article-title":"Suppression of HIV in the first 12 months of antiretroviral therapy: a comparative analysis of dolutegravir- and efavirenz-based regimens","volume":"21","author":"da Silva","year":"2023","journal-title":"einstein (Sao Paulo)"},{"issue":"8","key":"10.1016\/j.idnow.2025.105185_b0100","doi-asserted-by":"crossref","first-page":"e534","DOI":"10.1016\/S2352-3018(22)00173-4","article-title":"72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study","volume":"9","author":"Malaba","year":"2022","journal-title":"Lancet HIV"},{"issue":"5","key":"10.1016\/j.idnow.2025.105185_b0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/tmi.12685","article-title":"Growth in HIV-infected children on long-term antiretroviral therapy","volume":"21","author":"Feucht","year":"2016","journal-title":"Trop Med Int Health"}],"container-title":["Infectious Diseases Now"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666991925001642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T17:11:46Z","timestamp":1768065106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666991925001642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":21,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2666991925001642"],"URL":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105185","relation":{},"ISSN":["2666-9919"],"issn-type":[{"value":"2666-9919","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of dolutegravir-based regimen in HIV-infected children in a treatment center in a regional health facility in Cameroon","name":"articletitle","label":"Article Title"},{"value":"Infectious Diseases Now","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.idnow.2025.105185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105185"}}